Jupiter Neurosciences, Inc. Common Stock (JUNS) - Total Assets
Based on the latest financial reports, Jupiter Neurosciences, Inc. Common Stock (JUNS) holds total assets worth $5.56 Million USD as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore JUNS operating cash flow to total debt to assess how comfortably operating cash covers total debt obligations.
Jupiter Neurosciences, Inc. Common Stock - Total Assets Trend (2019–2025)
This chart illustrates how Jupiter Neurosciences, Inc. Common Stock's total assets have evolved over time, based on quarterly financial data. See Jupiter Neurosciences, Inc. Common Stock shareholders equity for net asset value and shareholders' equity analysis.
Jupiter Neurosciences, Inc. Common Stock - Asset Composition Analysis
Current Asset Composition (December 2025)
Jupiter Neurosciences, Inc. Common Stock's total assets of $5.56 Million consist of 86.7% current assets and 13.3% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 68.1% |
| Accounts Receivable | $2.64K | 0.1% |
| Inventory | $159.79K | 2.9% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2019–2025)
This chart illustrates how Jupiter Neurosciences, Inc. Common Stock's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Jupiter Neurosciences, Inc. Common Stock stock valuation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Jupiter Neurosciences, Inc. Common Stock's current assets represent 86.7% of total assets in 2025, an increase from 80.4% in 2019.
- Cash Position: Cash and equivalents constituted 68.1% of total assets in 2025, up from 20.7% in 2019.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2019.
- Asset Diversification: The largest asset category is inventory at 2.9% of total assets.
Jupiter Neurosciences, Inc. Common Stock Competitors by Total Assets
Key competitors of Jupiter Neurosciences, Inc. Common Stock based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX
|
USA | $8.68 Billion |
|
Royalty Pharma Plc
NASDAQ:RPRX
|
USA | $19.82 Billion |
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL
|
USA | $1.26 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578
|
China | CN¥8.59 Billion |
|
Apogee Therapeutics, Inc. Common Stock
NASDAQ:APGE
|
USA | $1.29 Billion |
|
Neuren Pharmaceuticals Ltd
AU:NEU
|
Australia | AU$331.25 Million |
|
Beijing Hotgen Biotech Co Ltd
SHG:688068
|
China | CN¥3.21 Billion |
Jupiter Neurosciences, Inc. Common Stock - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.65 | 1.91 | 0.13 |
| Quick Ratio | 0.63 | 1.91 | 0.13 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-2.57 Million | $1.72 Million | $-3.71 Million |
Jupiter Neurosciences, Inc. Common Stock - Advanced Valuation Insights
This section examines the relationship between Jupiter Neurosciences, Inc. Common Stock's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 227.66 |
| Latest Market Cap to Assets Ratio | 0.59 |
| Asset Growth Rate (YoY) | -10.3% |
| Total Assets | $5.56 Million |
| Market Capitalization | $3.27 Million USD |
Valuation Analysis
Below Book Valuation: The market values Jupiter Neurosciences, Inc. Common Stock's assets below their book value (0.59x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Jupiter Neurosciences, Inc. Common Stock's assets decreased by 10.3% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Jupiter Neurosciences, Inc. Common Stock (2019–2025)
The table below shows the annual total assets of Jupiter Neurosciences, Inc. Common Stock from 2019 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $5.56 Million | -10.29% |
| 2024-12-31 | $6.20 Million | +4074.12% |
| 2023-12-31 | $148.59K | -37.02% |
| 2022-12-31 | $235.94K | -64.65% |
| 2021-12-31 | $667.38K | +21.35% |
| 2020-12-31 | $549.98K | +8803.72% |
| 2019-12-31 | $6.18K | -- |
About Jupiter Neurosciences, Inc. Common Stock
Jupiter Neurosciences, Inc., a clinical stage research and development pharmaceutical company, engages in the development of therapeutics for central nervous system disorders and rare diseases in the United States and internationally. It operates in two segments, Pharmaceutical Operations and Premium Nutritional Supplements. The company researches and develops JNS115, which is in Phase IIa clinic… Read more